Current Perspectives Pharmacotherapy of Schizophrenia

Jarvik M.E. Drugs used in the treatment of psychiatric disorders. In: Goodman L.S. , Gilman A. , eds. The pharmacological basis of therapeutics, 4th edition. London: Macmillan Company, 1970.

Pickar D. Neuroleptics, dopamine and schizophrenia. Psychiatr Clin North Amer 1986; 9: 35–48.

Grigoriadis D. , Seeman P. The dopamine/neuroleptic receptor. Can J Neurol Sci 1984; 11(Suppl.): 108–113.

Walters J.R. , Bergstrom D.A. , Carlson J.H. D₁ dopamine receptor activation required for postsynaptic expression of D₂ agonist effects. Am Assoc Adv Sci 1987; 236: 719–722.

Seeman M.V. , Seeman P. Psychosis and positron tomography. Can J Psychiatry 1988; 33(4): 299–306.

Farde L. , Hall H. , Ehrin E. Quantitative analysis of D₂ dopamine receptor binding in the living human brain by PET. Science 1986; 231: 258–261.

Zemlan F.P. , Hitzemann R.J. , Hirschowitz J. Down-regulation of central dopamine receptors in schizophrenia. Am J Psychiatry 1985; 142: 1334–1337.

Richelson E. Neuroleptic affinities for human brain receptors and their use in predicting adverse effects. J Clin Psychiatry 1984; 45: 332–336.

Tarsy D. Neuroleptic-induced extrapyramidal reactions: classification, description and diagnosis. Clin Neuropharmacol 1983; 6(Suppl.): S9–S26.

Chouinard C. , Jones B.D. Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics. Am J Psychiatry 1980; 137: 16–21.

Hornykiewicz O. Brain catecholamines in schizophrenia — a good case for noradrenaline. Nature 1982; 299: 484–486.

Kokkinidis L. , Anisman H. Amphetamine models of paranoid schizophrenia: an overview and elaboration of animal experimentation. Psychol Bull 1980; 88: 551–579.

Stahl S.M. , Woo D.J. , Mefford I.N. Hyperserotonemia and platelet serotonin uptake and release in schizophrenia and affective disorders. Am J Psychiatry 1983; 140: 26–30.

Van Kammen D.P. γ-Aminobutyric acid (Gaba) and the dopamine hypothesis of schizophrenia. Am J Psychiatry 1977; 134: 138–143.

Seeman M.V. Pharmacologic features and effects of neuroleptics. Can Med Assoc J 1981; 125: 821–826.

Kane J.M. Treatment of schizophrenia. Schizophr Bull 1987; 13: 133–156.

Carpenter W.T. , Keith S.J. Integrating treatments in schizophrenia. Psychiatr Clin North Amer 1986; 9: 153–164.

Crow T.J. , Ferrier I.N. , Johnstone E.C. The two-syndrome concept and neuro-endocrinology of schizophrenia. Psychiatr Clin North Amer 1986; 9: 99–113.

Meltzer H.Y. , Somers A.A. , Luchins D.J. The effect of neuroleptics and other psychotropic drugs on negative symptoms in schizophrenia. J Clin Psychopharmacol 1986; 6: 329–338.

Turns D.M. , Pary R. , Tobias C.R. Depot neuroleptics for acutely psychotic patients. Am J Psychiatry 1987; 144: 1099.

Curry S.H. Commentary: the strategy and value of neuroleptic drug monitoring. J Clin Psychopharmacol 1985; 5: 263–271.

Settle E.C. Jr , Ayd F.J. Jr. Haloperidol: a quarter century of experience. J Clin Psychiatry 1983; 44: 440–448.

Gardos G. Are antipsychotics interchangeable? J Nerv Ment Dis 1974; 159: 343–348.

Baldessarini R.J. , Katz B. , Cotton P. Dissimilar dosaging with high-potency and low-potency neuroleptics. Am J Psychiatry 1984; 141: 748–752.

Keepers G.A. , Casey D.E. Prediction of neuroleptic-induced dystonia. J Clin Psychopharmacol 1987; 7: 342–345.

Boyer W.F. , Honeycutt Bakalar N. , Lake C.R. Anticholinergic prophylaxis of acute haloperidol-induced acute dystonic reactions. J Clin Psychopharmacol 1987; 7: 164–166.

Simpson G.M. , Pi E.H. , Sramek J.J. An update on tardive dyskinesia. Hosp Community Psychiatry 1986; 37: 362–369.

Chouinard G. , Steinberg S. Type I tardive dyskinesia induced by anticholinergic drugs, dopamine agonists and neuroleptics. Prog Neuropsychopharmacol Biol Psychiatry 1982; 6: 571–578.

Tecott L.H. , Kwong L.L. , Uhr S. Differential modulation of dopamine D₂ receptors by chronic Haloperidol, nitrendipine, and pimozide. Biol Psychiatry 1986; 21: 1114–1122.

Marder S.R. , Van Putten T. Who should receive Clozapine? Arch Gen Psychiatry 1988; 45: 865–867.

Badway M.A. , Dugas J.E. Loxapine yields amoxapine. J Clin Psychopharmacol 1984; 4: 363–364.

Baldessarini R.J. , Cohen B.M. , Teicher M.H. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry 1988; 45: 79–91.

Van Putten T. Why do schizophrenic patients refuse to take their drugs? Arch Gen Psychiatry 1974; 31: 67–72.

Torrey E.F. Management of chronic schizophrenic outpatients. Psychiatr Clin North Amer 1986; 9: 143–151.

Tupin J.P. Focal neuroleptization: an approach to optimal dosaging for initial and continuing therapy. J Clin Psychopharmacol 1985; 5(Suppl.): 15S–21S.

Salzman C. , Green A.I. , Rodriguez-Villa F. Benzodiazepines combined with neuroleptics for management of severe disruptive behavior. Psychosomatics 1986; 27: 17–21.

Dubin W.R. , Weiss K.J. , Dorn J.M. Pharmacotherapy of psychiatric emergencies. J Clin Psychopharmacol 1986; 6: 210–222.

Hooper J.F. Droperidol and acute psychosis. J Clin Psychopharmacol 1987; 7: 198.

Sorgi P.J. , Ratey J.J. , Polakoff S. β-adrenergic blockers for the control of aggressive behaviors in patients with schizophrenia. Am J Psychiatry 1988; 143: 775–776.

Lader M. β-adrenoceptor antagonists in neuropsychiatry: an update. J Clin Psychiatry 1988; 49: 213–223.

McCreadie R.G. , Mackie M. , Wiles D.H. Within-individual variation in steady state plasma levels of different neuroleptics and prolactin. Br J Psychiatry 1984; 144: 625–629.

McIntyre I.M. , Gershon S. Interpatient variations in antipsychotic therapy. J Clin Psychiatry 1985; 46: 3–5.

Remington G. , Pollock B. , Voineskos G. The emergency treatment of acutely psychotic patients: clinical and pharmacological correlates. Presented at the IVth World Congress of Biological Psychiatry, Philadelphia, Pennsylvania, September 8–13, 1985.

Ayd F.J. Jr. Guidelines for using intramuscular haloperidol for rapid neuroleptization. In: Ayd F.J. Jr , ed. Haloperidol update: 1958–1980. Baltimore: Ayd Medical Communications, 1980.

Menuck M. , Voineskos G. Rapid parenteral treatment of acute psychosis. Compr Psychiatry 1981; 22: 351–361.

Johnson D.A. , Kane J.M. , Simpson G. I. The use of depot neuroleptics: clinical experience in the United States and the United Kingdom. In: International Seminars on Depot and Oral Neuroleptics, Los Angeles, California: 1984.

Kane J.M. Dosage strategies with long-acting injectable neuroleptics, including haloperidol decanoate. J Clin Psychopharmacol 1986; 6(Suppl.): 20S–23S.

Marder S.R. Depot neuroleptics: side effects and safety. J Clin Psychopharmacol 1986; 6(Suppl.): 24S–29S.

Babiker I.E. Comparative efficacy of long-acting depot and oral neuroleptic medications in preventing schizophrenic recidivism. J Clin Psychiatry 1987; 48: 94–97.

Schooler N.R. Treatment of schizophrenia: maintenance strategies and pharmacologic tactics. In: Alpert M. , ed. Controversies in schizophrenia. New York: Guilford Press, 1985.

Carpenter W. Early, targeted pharmacotherapeutic intervention in schizophrenia. J Clin Psychiatry 1986; 47(Suppl.): 23–29.

Rivera-Calimlim L. , Hershey L. Neuroleptic concentrations and clinical response. Ann Rev Pharmacol Toxicol 1984; 24: 361–386.

Raskin D.E. Antipsychotic medication and the elderly. J Clin Psychiatry 1985; 46: 36–40.

Seeman M.V. Clinical and demographic correlates of neuroleptic response. Can J Psychiatry 1985; 304: 243–245.

Lin K-M , Finder E. Neuroleptic dosage for Asians. Am J Psychiatry 1983; 140: 490–491.

Potkin S.G. , Shen Y. , Pardes H. Haloperidol concentrations elevated in Chinese patients. Psychiatry Res 1984; 12: 167–172.

Sramek J.J. , Sayles M.A. , Simpson G.M. Neuroleptic dosage for Asians: a failure to replicate. Am J Psychiatry 1986; 143: 535–536.

Greendyke R.M. , Kanter D.R. Plasma propanolol levels and their effect on plasma thioridazine and haloperidol concentrations. J Clin Psychopharmacol 1987; 7: 178–182.

Jann M.W. , Saklad S.R. , Ereshefsky L. Effects of smoking on haloperidol and reduced haloperidol plasma concentrations and haloperidol clearance. Psychopharmacology 1986; 90: 468–470.

Fast D.K. , Jones B.D. , Kusalic M. Effect of carbamazepine on neuroleptic plasma levels and efficacy. Am J Psychiatry 1986; 143: 117–118.

Balant-Gorgia A.E. , Balant L. Antipsychotic drugs: clinical pharmacokinetics of potential candidates for plasma concentration monitoring. Clin Pharmacokinet 1987; 13: 65–90.

Mavroidis M.L. , Garver D.L. , Kanter D.R. Plasma haloperidol levels and clinical response: confounding variables. Psychopharmacol Bull 1985; 21: 62–65.

Rockland L.H. Neuroleptic blood levels and clinical response. Can J Psychiatry 1986; 31(4): 299–303.

Wode-Helgodt B. , Borg S. , Fyro B. Clinical effects and drug concentrations in plasma and cerebrospinal fluid in psychotic patients treated with fixed doses of chlorpromazine. Acta Psychiatr Scand 1978; 58: 149–173.

Rama Rao V.A. , Bishop M. , Coppen A. Clinical state, plasma levels of haloperidol and prolactin: a correlation study in chronic schizophrenia. Br J Psychiatry 1980; 137: 518–521.

Smith R.C. , Misra C.H. , Allen R. Dosage and blood levels of neuroleptics in tardive dyskinesia. Mod Probl Pharmacop-sychiat 1983; 21: 87–96.

Yesavage J.A. , Decker Tenke E. , Sheikh J.I. Tardive dyskinesia and steady-state serum levels of thiothixene. Arch Gen Psychiatry 1987; 44: 913–915.

Perry P.J. , Pfohl B.M. , Kelly M.W. The relationship of haloperidol concentrations to therapeutic response. J Clin Psychopharmacol 1988; 8: 38–43.

McEvoy J.P. The neuroleptic threshold as a marker of minimum effective neuroleptic dose. Compr Psychiatry 1986; 27: 327–335.

McEvoy J.P. , Stiller R.L. , Farr R. Plasma haloperidol levels drawn at neuroleptic threshold doses: a pilot study. J Clin Psychopharmacol 1986; 6: 133–138.

Csernansky J.G. , Kaplan J. , Hollister L.E. Problems in classification of schizophrenics as neuroleptic responders and non-responders. J Nerv Ment Dis 1985; 173: 325–331.

Lydiard R.B. , Knight Laird L. Prediction of response to antipsychotics. J Clin Psychopharmacol 1988; 8: 3–13.

Andreasen N.C. Negative symptoms in schizophrenia. Arch Gen Psychiatry 1982; 39: 784–788.

Kulhara P. , Chadda R. A study of negative symptoms in schizophrenia and depression. Compr Psychiatry 1987; 28: 229–235.

Breier A. , Wolkowitz O.M. , Doran A.R. Neuroleptic responsivity of negative and positive symptoms in schizophrenia. Am J Psychiatry 1987; 144: 1549–1555.

Henrichs D.W. , Hanlon T.E. , Carpenter W.T. The quality of life scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 1984; 10: 388–398.

Andreasen N.C. Positive vs negative schizophrenia: a critical evaluation. Schizophr Bull 1985; 11: 380–389.

Sommers A.A. “Negative symptoms”: conceptual and methodological problems. Schizophr Bull 1985; 11: 364–379.

Tang S.W. Prediction of treatment response in schizophrenia: clinical use of neuroleptic bloodlevels. Can J Psychiatry 1985; 30(4): 249–250.

Berrios G.E. Neuroleptic-refractory patients and their drug plasma levels. Encephale 1982; 8: 465–485.

Feinsilver D.B. , Yates B.T. Combined use of psychotherapy and drugs in chronic, treatment-resistant schizophrenic patients. J Nerv Ment Dis 1984; 172: 133–139.

Small J.G. , Kellams J.J. , Milstein V. A placebo-controlled study of lithium combined with neuroleptics in chronic schizophrenic patients. Am J Psychiatry 1975; 132: 1315–1317.

Goldberg S.C. Discussion of Dr. George Simpson's paper on pharmacological treatments of schizophrenia. Psychopharmacol Bull 1986; 22: 42–43.

DeLisi L.E. , Crow T.J. , Hirsch S.R. The third biannual winter workshop on schizophrenia. Arch Gen Psychiatry 1986; 43: 706–711.

Ortiz A. , Gershon S. The future of neuroleptic psychopharmacology. J Clin Psychiatry 1986; 47(Suppl.): 3–11.

Manchanda R. , Hirsch S.R. Does propanolol have an antipsychotic effect? A placebo-controlled study in acute schizophrenia. Br J Psychiatry 1986; 148: 701–707.

Berlant J.L. One more look at propanolol for the treatment of refratory schizophrenia. Schizophr Bull 1987; 34: 705–714.

Jimerson D.C. , Van Kammen D.P. , Post R.M. Diazepam in schizophrenia: a preliminary double-blind trial. Am J Psychiatry 1982; 139: 489–491.

Wolkowitz O.M. , Pickar D. , Doran A.R. Combination alprazolam-neuroleptic treatment of the positive and negative symptoms of schizophrenia. Am J Psychiatry 1986; 143: 85–87.

Raines J.M. , Greenspan D. Clonazepam in the treatment of chronic schizophrenia. Am J Psychiatry 1987; 144: 1510.

Kane J. , Honigfeld G. , Singer J. Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 1988; 45: 789–796.

Price W.A. , Pascarzi G. , Giannini A.J. Treatment of schizophrenia with verapamil. J Clin Psychopharmacol 1986; 6: 249.

Pickar D. , Wolkowitz O.M. , Doran A.F. Clinical and biochemical effects of verapamil administration to schizophrenic patients. Arch Gen Psychiatry 1987; 44: 113–118.

Sacks W. , Cowen M.A. , Green M.R. Acetazolamide and thiamine (A+T): a preliminary report of an ancillary therapy for chronic mental illness. J Clin Psychopharmacol 1988; 8: 70.

Beauclair L. , Vinogradov S. , Riney S.J. An adjunctive role for ascorbic acid in the treatment of schizophrenia? J Clin Psychopharmacol 1987; 7: 282–283.

Brizer D.A. , Hartman N. , Sweeney J. Effect of methadone plus neuroleptics on treatment-resistant chronic schizophrenia. Am J Psychiatry 1985; 142: 1106–1107.

Iager A-C , Kirch D.G. , Bigelow L.B. Treatment of schizophrenia with a vasopressin analogue. Am J Psychiatry 1986; 143: 375–377.

Kendell R.E. The present status of eletroconvulsive therapy. Br J Psychiatry 1981; 139: 265–283.

Martin B.A. Electroconvulsive therapy: contemporary standards of practice. Can J Psychiatry 1986; 31(8): 759–771.

Abraham K.R. , Kulhara P. The efficacy of electroconvulsive therapy in the treatment of schizophrenia. Br J Psychiatry 1987; 151: 152–155.

Brambilla F. , Scarone S. , Pugnetti L. Bromocriptine therapy in chronic schizophrenia: effects on symptomatology, sleep patterns, and prolatin response to stimulation. Psychiatr Res 1983; 8: 159–169.

Hommer D.W. , Pickar D. , Roy A. The effects of cerule-tide in schizophrenia. Arch Gen Psychiatry 1984; 41: 617–619.

Cohen J.D. , Van Putten T. , Marder S. The efficacy of piquindone, a new atypical neuroleptic, in the treatment of the positive and negative symptoms of schizophrenia. J Clin Psychopharmacol 1987; 7: 324–329.

Chaimowitz G.A. , Gomes U. , Maze S.S. Neuroleptic malignant syndrome. Can Med Assoc J 1988; 138: 51–52.

Pope H.G. , Cole J.O. , Choras P.T. Apparent neuroleptic malignant syndrome with clozapine and lithium. J Nerv Ment Dis 1986; 174: 493–495.

Moore N.C. , Meyendorff E. , Yeragani V. Tiaspirone in schizophrenia. J Clin Psychopharmacol 1987; 7: 98–101.

Chouinard G. Early phase II clinical trial of remoxipride in treatment of schizophrenia with measurements of prolactin and neuroleptic activity. J Clin Psychopharmacol 1987; 3: 159–164.

Gravem M. , Eigen K. Cis (Z)-Clopenthixol: the neuroleptically active isomer of clopenthixol. Acta Psychiatr Scand (Suppl) 1981; 64: 5–77.

Amdisen A. , Nielsen M.S. , Dencker S.J. Zuclopenthixol acetate in Viscoleo — a new drug formulation. Acta Psychiatr Scand 1987; 75: 99–107.

Pall H.S. , Blake D.R. , Williams A.C. Evidence of enhanced lipid peroxidation in the cerebrospinal fluid of patients taking phenothiazines. Lancet 1987; ii: 596–599.

Donlon P.T. , Stenson R.L. Neuroleptic induced extrapyramidal symptoms. Dis Nerv. Syst 1976; 37: 629–635.

McEvoy J.P. The clinical use of anticholinergic drugs as treatment for extrapyramidal side effects of neuroleptic drugs. J Clin Psychopharmacol 1983; 3: 288–302.

Jellinek T. , Gardos G. , Cole J.O. Adverse effects of antiparkinsonian drug withdrawal. Am J Psychiatry 1981; 138: 1567–1571.

Ayd F.J. Jr. A survey of drug-induced extrapyramidal reactions. JAMA 1961; 175: 1054–1060.

Barnes T.R.E. The present status of tardive dyskinesia and akathisia in the treatment of schizophrenia. Psychiatr Dev 1987; 4: 301–319.

Barnes T.R.E. , Braude W.M. Akathisia variants and tardive dyskinesia. Arch Gen Psychiatry 1985; 42: 874–878.

Munetz M.R. , Comes C.L. Akathisia, pseudoakathisia and tardive dyskinesia: clinical examples. Compr Psychiatry 1982; 23: 345–352.

Patterson J.F. Pseudoakathisia associated with atenolol. J Clin Psychopharmacol 1986; 6: 390.

Barnes T.R.E. , Braude W.M. Persistent akathisia associated with early tardive dyskinesia. Postgrad Med J 1984; 60: 359–361.

Braude W.M. , Barnes T.R.E. Late-onset akathisia — an indicant of covert dyskinesia: two case reports. Am J Psychiatry 1983; 140: 611–612.

Pall H.S. , Williams A.C. , Blake Dr. Iron, akathisia, and antipsychotic drugs. Lancet 1986; ii: 1469.

Blake D.R. , Williams A.C. , Pall H.S. Iron and akathisia. Br Med J 1986; 292: 1393.

Brown K.W. , Glen S.E. , White T. Low serum iron status and akathisia. Lancet 1987; i: 1234–1236.

Editorial. Akathisia and antipsychotic drugs. Lancet 1986; ii: 1131–1132.

Ball R. Drug-induced akathisia: a review. J R Soc Med 1985; 78: 748–752.

Gillman M.A. , Sandyk R. , Lichtigfeld F.J. Evidence for underactivity of the opioid system in neuroleptic-induced akathisia. Psychiatr Res 1984; 13: 187.

Ratey J.J. , Salzman C. Recognizing and managing akathisia. Hosp Community Psychiatry 1984; 35: 975–977.

Adler L. , Angrist B. , Peslow E. A controlled assessment of propanolol in the treatment of neuroleptic-induced akathisia. Br J Psychiatry 1986; 149: 42–45.

Gelenberg A.J. Treating extrapyramidal reactions: some current issues. J Clin Psychiatry 1987; 48(Suppl.): 24–27.

Adler L. , Angrist B. , Peselow E. Noradrenergic mechanisms in akathisia: treatment with propanolol and Clonidine. Psychopharmacol Bull 1987; 23: 21–25.

Zubenko G.S. , Cohen B.M. , Lipinski J.F. Jr. Use of Clonidine in treating neuroleptic-induced akathisia. Psychiatry Res 1984; 13: 253–259.

Bartels M. , Heide K. , Mann K. Treatment of akathisia with lorazepam: an open clinical trial. Pharmacopsychiatry 1987; 20: 51–53.

Kutcher S.P. , Mackenzie S. , Galarraga W. Clonazepam treatment of adolescents with neuroleptic-induced akathisia. Am J Psychiatry 1987; 144: 823–824.

Barnes T.R.E. The present status of tardive dyskinesia and akathisia in the treatment of schizophrenia. Psychiatr Dev 1987; 4: 301–319.

Friedman J.H. , Wagner R.L. Akathisia: the syndrome of motor restlessness. Am Fam Physician 1987; 35: 145–149.

Kabes J. , Sikora J. , Pisvejc J. Effect of piracetam on extrapyramidal side effects induced by neuroleptic drugs. Int Pharmacopsychiatry 1982; 17: 185–192.

Tollefson G. A case of neuroleptic malignant syndrome: in vitro muscle comparison with malignant hyperthermia. J Clin Psychopharmacol 1982; 2: 266–270.

Kurlan R. , Hamill R. , Shoulson I. Neuroleptic malignant syndrome. Clin Neuropharmacol 1984; 7: 109–120.

Weinberg S. , Twersky B.A. Neuroleptic malignant syndrome. Anesth Analg 1983; 62: 848–850.

Sternberg D.E. Neuroleptic malignant syndrome: the pendulum swings. Am J Psychiatry 1986; 143: 1273–1275.

Jee A. Neuroleptic malignant syndrome: facts and controversies. Am J Psychiatry 1987; 144: 1104.

Pearlman C.A. Neuroleptic malignant syndrome: a review of the literature. J Clin Psychopharmacol 1986; 6: 257–263.

Shalev A. , Hermesh H. , Munitz H. The role of loading rate in neuroleptic malignant syndrome. Am J Psychiatry 1986; 143: 1059.

Merriam A.E. Neuroleptic malignant syndrome after Imipramine withdrawal. J Clin Psychopharmacol 1987; 7: 53–54.

Simpson D.M. , Davis G.C. Case report of neuroleptic malignant syndrome associated with withdrawal from amantadine. Am J Psychiatry 1984; 141: 796–797.

Hamburg P. , Weilburg J.B. , Cassem N.H. Relapse of neuroleptic malignant syndrome with early discontinuation of amantadine therapy. Compr Psychiatry 1986; 27: 272–275.

Gabuzda D.H. , Frankenburg F.R. Fever caused by lithium in a patient with neuroleptic malignant syndrome. J Clin Psychopharmacol 1987; 7: 283–284.

Levenson J.L. , Fisher J.G. Long-term outcome after neuroleptic malignant syndrome. J Clin Psychiatry 1988; 49: 154–156.

Shalev A. , Hermesh H. , Aizenberg D. Neuroleptic malignant syndrome. N Engl J Med 1985; 313: 1292–1293.

Lavie C.J. , Ventura H.O. , Walker G. Neuroleptic malignant syndrome: three episodes with different drugs. South Med J 1986; 79: 1571–1573.

Addonizio G. , Susman V.L. ECT as a treatment alternative for patients with symptoms of neuroleptic malignant syndrome. J Clin Psychiatry 1987; 48: 102–105.

Kane J.M. , Smith J.M. Tardive dyskinesia: prevalence and risk factors, 1959 to 1979. Arch Gen Psychiatry 1982; 39: 473–481.

Tarsy D. Movement disorders with neuroleptic drug treatment. Psychiatr Clin North Amer. 1984; 7: 453–471.

Seeman M. Tardive dyskinesia: two-year recovery. Compr Psychiatry 1981; 22: 189–192.

DeVeaugh-Geiss J. Clinical changes in tardive dyskinesia during long-term follow up. Presented at the 140th Annual Meeting of the American Psychiatric Association, Chicago, May 9–14, 1987.

Casey D.E. , Povisen U.J. , Meidahl B. Neuroleptic-induced tardive dyskinesia and parkisonism: changes during several years of continuing treatment. Psychopharmacol Bull 1986; 22: 250–253.

Chouinard G. , Annable L. , Mercier P. A five-year follow-up study of tardive dyskinesia. Psychopharmacol Bull 1986; 22: 259–263.

Yassa R. , Samarthji L. , Korpassy A. Nicotine exposure and tardive dyskinesia. Biol Psychiatry 1987; 22: 67–72.

Youssef H.A. , Waddington J.L. Morbidity and mortality in tardive dyskinesia: associations in chronic schizophrenia. Acta Psychiatr Scand 1987; 75: 74–77.

Waddington J.L. , Youssef H.A. Late onset involuntary movements in chronic schizophrenia: relationship of ‘tardive’ dyskinesia to intellectual impairment and negative symptoms. Br J Psychiatry 1986; 149: 616–620.

Waddington J.L. , Youssef H.A. , Dolphin C. Cognitive dysfunction, negative symptoms, and tardive dyskinesia in schizophrenia. Arch Gen Psychiatry 1987; 44: 907–912.

Berger P.A. , Rexroth K. Tardive dyskinesia: clinical, biological, and pharmacological perspectives. Schizophr Bull 1980; 6: 102–116.

Nasrallah H.A. , Dunner F.J. , McCalley-Whitters M. Pharmacologic probes of neurotransmitter systems in tardive dyskinesia: implications for clinical management. J Clin Psychiatry 1986; 47: 56–59.

Wolkin A. , Jordan B. , Peselow E. Essential fatty acid supplementation in tardive dyskinesia. Am J Psychiatry 1986; 143: 912–914.

Sandyk R. , Snider S.R. Naloxone and tardive dyskinesia. Biol Psychiatry 1985; 20: 1335–1336.

Jeste D.V. , Wyatt R.J. Understanding and treating tardive dyskinesia. New York: Guilford Press, 1982.

Thaker G.V. , Tamminga C.A. , Alphs L.D. Brain γ-aminobutyric acid abnormality in tardive dyskinesia. Arch Gen Psychiatry 1987; 44: 522–529.

Csernansky J.G. , Tacke U. , Rusen D. The effect of benzodiazepines on tardive dyskinesia syndromes. J Clin Psychopharmacol 1988; 8: 154.

Browne J. , Silver H. , Martin R. The use of Clonidine in the treatment of neuroleptic-induced tardive dyskinesia. J Clin Psychopharmacol 1986; 6: 88–92.

Gross L. , Schorr L. , Rosenblatt J.E. Improvement of tardive dyskinesia with isosorbide dinitrate. J Clin Psychopharmacol 1986; 6: 247–248.

Wright J. , Schrodt R. , Simpson D. Propanolol treatment of tardive dyskinesia. Presented at the Ulrd World Congress of Biological Psychiatry, Stockholm, June, 1981.

El-Awar M. , Freedman M. , Seeman P. Response of tardive and 1-dopa-induced dyskinesias to antidepressants. Can J Neurol Sci 1984; 11(Suppl.): 108–113.

Barrow N. , Childs A. An anti-tardive dyskinesia effect of verapamil. Am J Psychiatry 1986; 143: 1485.

Ross J.L. , Mackenzie T.B. , Hanson D.R. Diltiazem for tardive dyskinesia. Lancet 1987; i: 268.

Yassa R. , Nair V. , Dimitry R. Prevalence of tardive dystonia. Acta Psychiatr Scand 1986; 73: 629–633.

Koller W.C. Tardive dystonia: diagnosis and treatment. Presented at the 140th Annual Meeting of the American Psychiatric Association, Chicago, May 9–14, 1987.

Remington G. The Pisa syndrome; possible role for serotonin and noradrenaline. J Clin Psychopharmacol 1988; 8: 228–229.

Burke R.E. , Fahn S. , Jankovic J. Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs. Neurology 1982; 32: 1335–1346.

Weiner W.J. , Luby E.D. Tardive akathisia. J Clin Psychiatry 1983; 44: 417–419.

Goldberg E. Akinesia, tardive dysmentia, and frontal lobe disorder in schizophrenia. Schizophr Bull 1985; 11: 255–263.

Koczapski A.B. , Ashby Y.T. , Ibraheem S. ‘Afternoon radiator-sitting syndrome’: hypothermia and early diagnosis of self-induced water intoxication. Br J Psychiatry 1987; 151: 133–134.

Jeste D.V. , Wisniewski A.A. , Wyatt R.J. Neuroleptic-associated tardive syndromes. Psychiatr Clin North Am 1986; 9: 183–192.